Osteoporosis Trial, Completed NCT00111241 Sponsor: Monash University Condition: Osteoporosis
Back to Osteoporosis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial involved two groups of women: 45 women who had breast cancer and 70 healthy women used as a comparison group. The trial was measuring changes in the knee joint over two years — specifically the amount of cartilage (the cushioning tissue in the knee) and the size of the bone surface just beneath that cartilage. Of those who started, 30 of the 45 women in the breast cancer group and 62 of the 70 women in the healthy group completed the study. The reported data shows that, for knee cartilage volume (measured in cubic millimetres, a unit of volume), the breast cancer group returned a figure of 2,042 mm³ compared with 1,971 mm³ for the healthy comparison group. For the secondary measure — the area of the bone surface just below the knee cartilage (measured in square millimetres) — the reported figures were 2,020 mm² for the breast cancer group and 1,992 mm² for the healthy comparison group. These numbers represent the reported values at the end of the two-year measurement period, though the data submitted does not include further detail about how the change over time was calculated or whether the difference between the two groups was considered meaningful by the researchers. It is worth noting that 15 women in the breast cancer group did not complete the study, which the data does not explain further. No information about the reasons for non-completion was reported in the structured data provided. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Osteoporosis Trial, Completed

NCT00111241
Completed Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 (main group):

  • You are between 40 and 65 years old
  • You are a woman who has had breast surgery and still has your uterus (you have not had a hysterectomy)
  • You have been taking aromatase inhibitor medication (a type of hormone-blocking drug used after breast cancer treatment) within the last 12 weeks

Group 2 (comparison/control group):

  • You are a healthy woman between 40 and 65 years old who still has your uterus (you have not had a hysterectomy)

Who may not be able to join:

  • You have previously injured your knee badly enough to need crutches or to avoid putting weight on it for more than 24 hours, or you have had any knee surgery including keyhole surgery
  • You are unable to complete the full study, for example because you are planning to move away from the area
  • You have a pacemaker, metal stitches, shrapnel in your body, or metal particles in your eye, which would make having an MRI scan unsafe
  • You have claustrophobia (fear of enclosed spaces, which may make having an MRI difficult)

Additional reasons Group 1 participants may not be able to join:

  • You have been taking a drug called tamoxifen for more than 8 weeks before the study starts
  • You have had knee pain lasting longer than 24 hours at any point in the last 5 years (before starting your current hormone-blocking medication)
  • You have been taking anastrozole or letrozole (types of aromatase inhibitors) for more than 12 weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Susan Davis, MBBS PhD, Director Women's Health Program

Australian sites

Women's Health Research Program, Monash University, The Alfred Hospital, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Monash University
Registry
ClinicalTrials.gov
Start date
1 May 2005
Est. completion
1 May 2011

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Knee Cartilage Volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov